A possible target for broad-range HPV therapeutics emerges

(Medical Xpress) -- Among viruses, human papilloma virus (HPV) stands out: with more than 180 distinct isotypes or variations catalogued to date, it presents an extremely difficult target for broad-range treatments. And while the HPV vaccine provides protection against the most common HPV infections, it only covers four of the 180-plus isotypes.

But now a University at Buffalo microbiologist has identified a that could present the first viable, broad-range HPV . This in the viral system is not only necessary for HPV synthesis, it is highly conserved between all HPV isotypes.

To find out if this interaction might be the basis of a drug that would work against all HPV isotypes, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded a $1.65 million grant to Thomas Melendy, PhD, associate professor in the Department of Microbiology and Immunology and the Department of Biochemistry in the UB School of Medicine and Biomedical Sciences.

"Currently, no antiviral drugs exist that act directly against HPV," says Melendy, whose laboratory is a world leader in identifying critical interactions between the HPV proteins and human proteins that the virus uses to duplicate . His work explains why HPV, unlike other DNA viruses, integrates so readily into the genome of human cells.

The target Melendy and his colleagues have identified is E1, a protein found in all HPV isotypes.

"E1 is a protein encoded for in the that interacts with human-DNA synthesis proteins and enzymes," explains Melendy. "It is found in all 180-plus HPV isotypes and it essentially 'reprograms' our synthesis machinery to start synthesizing HPV genomes once our cells are infected."

In particular, Melendy has been studying a protein-protein interaction called E1-Topol in which E1 interacts with the human enzyme Topol (Topoisomerase I).

In 2010, Melendy identified individual amino acids within the HPV E1 protein that he suspected were critical for the interactions with Topol. His lab created a mutation of E1 that altered a single amino acid within this conserved domain. Melendy's colleague, Jacques-Archambault, director of the Institut de Recherches Cliniques de Montreal, tested this mutation in a cell-culture HPV DNA synthesis system he had developed.

"The result provided the proof-of-principle we were seeking," says Melendy, "demonstrating, as I had predicted, that this E1 mutant was dramatically compromised for HPV DNA synthesis, thus proving that if we could find a way to interfere with this E1-Topol interaction, it should prevent the HPV virus from reproducing."

It turned out that that interaction domain on E1 is one of the most conserved protein sequences across all HPV isotypes. "That suggested that if we can find a way to interfere with this interaction, we could affect all HPV isotypes and not just some," says Melendy.

The new grant funds research designed to further analyze this interaction in order to find out how best to attack it. In addition to Melendy, other investigators on the grant include Archambault and Vivian Cody, PhD, principal scientist at Hauptman-Woodward Medical Research Institute and UB professor of structural biology, who will attempt to co-crystallize Topol with the domain of E1 that interacts with Topol in order to visualize the interaction at the atomic level.

All of this information will then be used to develop a more refined series of small molecules designed to interfere with the E1-Topol interaction, with the ultimate goal of developing a broad-range anti-HPV drug.

"For individuals with persistent , which has recently been found to be a particular problem among African-American women, for example, a treatment that works against an ongoing HPV infection and that acts against all HPV isotypes is exactly what is needed," says Melendy.

add to favorites email to friend print save as pdf

Related Stories

'Get vaccinated,' says HPV expert at UB Medical School

Oct 11, 2011

(Medical Xpress) -- A University at Buffalo microbiologist whose lab has been studying the human papilloma virus for years, says that parents should have their children vaccinated with Gardasil, the HPV vaccine.

Study explores attitudes and beliefs about HPV

Mar 01, 2007

The most common sexually transmitted virus in the US is genital human papillomavirus (HPV) infection, with 20 million Americans currently infected and another 6.2 million becoming infected each year. Although HPV causes serious ...

Oral HPV infection, HPV-related cancers more common in men

Jan 26, 2012

Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer ...

HIV drug could prevent cervical cancer

May 03, 2011

A widely used HIV drug could be used to prevent cervical cancer caused by infection with the human papilloma virus (HPV), say scientists.

Recommended for you

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

10 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Cancer exosome 'micro factories' aid in cancer progression

14 hours ago

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

User comments